4313-74-0

Usage

Uses

Used in Biochemistry and Bioorganic Chemistry Research:
L-Leucine, N-D-phenylalanyl-, methyl ester is used as a research tool for its ability to aid in the understanding of biochemical processes and the synthesis of complex organic compounds.
Used in Peptide and Protein Synthesis:
L-Leucine, N-D-phenylalanyl-, methyl ester is used as a building block in the synthesis of peptides and proteins, contributing to the development of new bioactive molecules and therapeutic agents.
Used in Pharmaceutical Development:
L-Leucine, N-D-phenylalanyl-, methyl ester is used in the development of pharmaceuticals, particularly for its potential in drug delivery and controlled release systems, enhancing the efficacy and targeted delivery of drugs.
Used in Drug Delivery Systems:
In the pharmaceutical industry, L-Leucine, N-D-phenylalanyl-, methyl ester is used as a component in drug delivery systems to improve the bioavailability and therapeutic outcomes of various medications.
Used in Cellular Process Studies:
L-Leucine, N-D-phenylalanyl-, methyl ester is used to study its interactions with biological systems and its potential effects on cellular processes, providing insights into the role of amino acids and peptides in physiological and pathological conditions.

Upstream product

• 2666-93-5 (S)-Leu-OMe 

Downstream Products

• 1632323-06-8 (S)-methyl 2-((R)-2-acrylamido-3-phenylpropanamido)-4-methylpentanoate 
• 1632323-09-1 (S)-methyl 2-((R)-2-(3-(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)propanamido)-3-phenylpropanamido)-4-methylpentanoate 
• 132478-01-4 (S)-1-[(S)-2-((S)-2-{(R)-2-[(S)-2-((S)-2-Amino-3-hydroxy-propionylamino)-3-(4-hydroxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-4-methyl-pentanoylamino)-5-guanidino-pentanoyl]-pyrrolidine-2-carboxylic acid carbamoylmethyl-amide 

Relevant academic research and scientific papers

Tryptophan-containing dipeptide derivatives as potent PPARγ antagonists: Design, synthesis, biological evaluation, and molecular modeling

The discovery of peroxisome proliferator-activated receptor γ (PPARγ) antagonists (also termed "selective PPARγ modulators, SPPARγM") is now of a great interest in the treatment of diabetes and obesity. The structure of compound 1a (G3335, Fig. 1), a novel class of PPARγ antagonist, is entirely different from that of other reported PPARγ antagonists. A series of 35 novel analogues (1b-l, 9a-d, 13a-t) were designed, synthesized and evaluated against the agonistic effects exerted by rosiglitazone. These results indicated that most functional groups of 1a were conserved, and six new compounds (1b, 1c, and 9a-d) exhibited strong PPARγ antagonistic activities (IC50 values of 5.2-25.8 μM) against 10 μM rosiglitazone in the promotion of the PPARγ-LBD-CBP (ligand-binding domain and cAMP-response-element binding protein) interaction as investigated by yeast two-hybrid technology based assay. Molecular modeling studies for compounds 1a-d, 1h, 9c-d, and 13a were also presented.

Nonapeptides and methods for their production

New nonapeptides having the formula Prot Grp-R-Trp-Ser-Tyr-R2 -Leu-Arg-Pro-Gly-R3 ; salts thereof; wherein R is Gln, Gln (bzl), His (bzl), Ser (bzl), Pro, Leu, Tyr (bzl), Ile, Cys (bzl) or Phe, R2 is D-Phe, D-Ala, D-Leu, D-Trp, D-Tyr, D-Tyr (Me), D-Ser, D-Met, D-Arg, D-Val, D-His, D-Gln, D-Phs, D-Thr, D-Pro or D-Asn and R3 is NH2, NH(lower alkyl) or N-(lower alkyl)2, methods for their production; certain peptide intermediates and their salts used in the production thereof; and the use of said nonapeptides as luteinizing hormone releasing factor antagonists.